Shafiqur Rahman

Education

Ph.D., Neuropharmacology, Memorial University of Newfoundland, Canada
Postdoctoral Fellowship in Neuropsychopharmacology, Department of Psychiatry,
Indiana University School of Medicine, Indianapolis, USA

Academic Interests

Pharmacology; Neuropharmacology; Drug Addiction; Therapeutic Drug Discovery for Neuropsychiatric and Neurological Disease; Public Health Policy on Drug Addiction and Mental Illness; Neuroethics; Neurotheology; Higher Education

Academic Responsibilities

TEACHING RESPONSIBILITIES FOR PROFESSIONAL PHARM.D. and GRADUATE PROGRAM in PHARMACEUTICAL SCIENCES:
Pathophysiology, Pharmacology, Toxicology-I (PHA 352)
Pathophysiology, Pharmacology, Toxicology-II (PHA 353)
Pathophysiology, Pharmacology, Toxicology-III (PHA 452)
Pathophysiology, Pharmacology, Toxicology-IV (PHA 453)
Drugs of Abuse and Addiction (PHA 752)
Pharmacology I (PHA 442)
Pharmacology II (PHA 443)
Topics in Pharmaceutical Sciences (PHA 825)
Advanced Concepts in Pharmacology (PHA 840)
Topics in Advanced Pharmacology (PHA 845)
Techniques in Pharmaceutical Sciences (PHA 846)
Seminar in Pharmaceutical Sciences (PHA 890)
Introduction to Pharmaceutical Sciences (PHA 720)
Medications and Wellness (PHA 201)

Committee Activities

Served as Chair, Vice-Chair, Member, Director on Numerous Institutional, Professional and Community Service Related Committees Since 2008.

Awards and Honors

SELECTED LIST OF AWARDS AND RECOGNITION:
Human and Civil Rights Award from South Dakota Education Association/National Education Association (2019)
Community Engagement Award, College of Pharmacy, South Dakota State University (2018)
Academic Leadership Fellow, American Association of Colleges of Pharmacy (2015-2016)
Distinguished Service Award, National Association on Mental Illness-South Dakota Chapter (2014)
TRiO Students’ Choice Award for Teaching, South Dakota State University (2013)
Distinguished Scholar and Researcher, College of Pharmacy, South Dakota State University (2010)
Fellow, American Foundation for Pharmaceutical Education (2008)
Clarke Foundation Postdoctoral Fellowship, University of Toronto, Canada
Fellow, School of Graduate Studies, Memorial University of Newfoundland, Canada
Memorial University of Newfoundland School of Medicine Graduate Fellowship, Canada
Swedish Government Travel Fellowship for Higher Education

Grants

RESEARCH GRANTS/SUPPORT RECEIVED AS PI/CO-PI and ADVISOR/MENTOR FOR CURRENT/PAST RESEARCH FROM THE FOLLOWING FUNDING AGENCIES/ORGANIZATIONS:
NIH/National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH/National Institute on Drug Abuse (NIDA)
Fulbright Foundation, USA
American Foundation for Pharmaceutical Education (AFPE)
American Association of Colleges of Pharmacy (AACP)
Saudi Arabia Cultural Mission (SACM), Washington DC, USA
Addiction Research Foundation
Avera Research Institute/Avera Research Foundation
South Dakota Research & Development Innovation Grant/South Dakota Board of Regents
South Dakota State University (SDSU) Research Foundation
SDSU Academic Excellence Fund
SDSU Research Support Fund
SDSU Juhnke Endowment Fund
South Dakota Governor's 2010 Research Initiative Fund
University of Kentucky Research Foundation
Clark Foundation, University of Toronto, Canada
Canadian Institutes of Health Research

Professional Memberships

Society for Neuroscience (SFN)
American Society for Experimental Neurotherapeutics (ASENT)
American Society for Pharmacology and Experimental Therapeutics (ASPET)
American Association of Colleges of Pharmacy (AACP)
American Association of Pharmaceutical Scientists (AAPS)
International Brain Research Organization (IBRO)
Novel Global Community Educational Foundation (NGCEF)
Rho Chi Pharmacy Honor Society
Sigma Xi Scientific Research Society

ADDITIONAL PROFESSIONAL ACTIVITIES (SELECTED LIST):
Regional Editor, CNS Neurological Disorders-Drug Targets (2016-present)
Editor, Effects of Peri-Adolescent Licit and Illicit Drug Use on the Developing CNS/International Review of Neuroscience (2020)
Editor, Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside/Progress in Molecular Biology and Translational Science (2018)
Editor, Molecular Basis of Drug Addiction/Progress in Molecular Biology and Translational Science (2015)
Editor, Animal Models for Medications Screening to Treat Addiction/International Review of Neurobiology (2016)
Editor, Brain as a Drug Target/Progress in Molecular Biology and Translational Science (2011)
Editor, Drug Addiction and Brain Targets from Preclinical Research to Pharmacotherapy/CNS & Neurological Disorders-Drug Targets (2009)

EDITORIAL BOARD MEMBER (2008-PRESENT):
International Review of Neurobiology
International Journal of Physiology, Phathophysiology and Pharmacology (IJPPP)
Current Drug Research Review
Drug Discoveries and Therapeutics
Current Drug Abuse Review
Journal of Addiction Research and Therapy
Frontiers Journals in Neuropharmacology
Aging and Neurodegeneration

OTHER ROLES/RESPONSIBILITIES:
Reviewer for 40 Scientific Journals related to drug addiction, neuroscience, pharmacology, and drug discovery research
Evaluator, Accreditation Council for Pharmacy Education (ACPE) (2017)
Secretary/Treasurer, American Society for Pharmacology and Experimental Therapeutics (ASPET)-Division of Pharmacology Education (2018-2020)
Co-Chair, Teaching Institute for Graduate Pharmacology Education, American Society for Pharmacology and Experimental Therapeutics (ASPET) at the Experimental Biology Meeting in San Diego (2018)
Invited Speaker, Target Discovery World Congress, San Francisco, USA (2008)

Area(s) of Research

Medication development for drug addiction and CNS disorders
Drug discovery for neuropsychiatric disorders
Drug discovery for neuroinflammatory and neuropathic pain
Substance use disorder and co-morbid mental illness

PEER-REVIEWED PUBLICATIONS INCLUDING RESEARCH ARTICLES, BOOKS/BOOK CHAPTERS
[SELECTED FROM >166; IN REVERSE CHRONOLOGICAL ORDER]:
*Corresponding Author

Donlon J, Kumari P, Varghese SP, and others, Rahman S, Stone TW, Koola MM, Integrative Pharmacology in the Treatment of Substance Use Disorders. J Dual Diagnosis 2023 Dec 20:1-46.
doi: 10.1080/15504263.2023.2293854.

Chen G, Rahman S, Lutfy K. E-cigarettes may serve as a gateway to conventional cigarettes and other addictive drugs. Adv. Drug Alcohol Res. 3:11345 (2023). doi:10.3389/adar.2023.11345.

Alotaibi G, Khan A, Ronan PJ, Lutfy K, Rahman S*. Glial Glutamate Transporter Modulation Prevents Development of Complete Freund’s Adjuvant-Induced Hyperalgesia and Allodynia in Mice. Brain Sci. 13(5), 807 (2023). doi:10.3390/brainsci13050807.

Tolentino L, Iqbal A, Rahman S, Lutfy K. The Role of Beta-Endorphin in Food Deprivation-Mediated Increases in Food Intake and Binge-Eating. Brain Sciences 13(2):212 (2023). doi:10.3390/brainsci13020212

Islam N, Cichero E, Rahman S, Ranasinghe I. Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation. Am J Cardiovasc Drugs. 23, 1-7 (2023). doi: 10.1007/s40256-022-00551-8.

Alzarea S, Abbas M, Ronan PJ, Lutfy K, Rahman S*. The Effect of an α-7 Nicotinic Allosteric Modulator PNU120596 and NMDA Receptor Antagonist Memantine on Depressive-like Behavior Induced by LPS in Mice: The Involvement of Brain Microglia. Brain Sci. 12 (11):1493 (2022). doi: 10.3390/brainsci12111493

Kumar D, Sharma A, Taliyan R, Urmera MT, Herrera-Calderon O, Heinbockel T, Rahman S, Goyal R. Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. Ageing Res Rev. 73, 101533 (2022). doi: 10.1016/j.arr.2021.101533.

Rahman S*, Rahman ZI, Ronan PJ, Lutfy K, Bell RL. Adolescent Opioid Abuse: Role of Glial and Neuroimmune Mechanisms. International Review of Neurobiology 161, 147-165 (2021). doi: 10.1016/bs.irn.2021.07.003.

Islam N, Rahman S*. Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease. Current Drug Delivery 19, 260-265 (2022). doi: 10.2174/1567201818666210331121803.

Tschetter KE, Callahan LB, Flynn SA, Rahman S, Beresford TP, Ronan PJ. Early life stress and susceptibility to addiction in adolescence. Int Rev Neurobiol. 161:277-302 (2021). doi: 10.1016/bs.irn.2021.08.007.

Rahman S*, Bell RL. Future directions for part I: Substance use disorder in adolescence-A vision for a better future. Int Rev Neurobiol 160, 341-344 (2021). doi: 10.1016/bs.irn.2021.08.008.

Abbas M, Alzarea S, Papke RL, Rahman S*. Effects of α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator on BDNF, NKCC1 and KCC2 Expression in the Hippocampus following Lipopolysaccharide-induced Allodynia and Hyperalgesia in a Mouse Model of Inflammatory Pain. CNS Neurol Disord Drug Targets 20, 366-377 (2021).
doi:10.2174/1871527319666201230102616.

Chen G, Ghazal M, Rahman S, Lutfy K. The Impact of Adolescent Nicotine Exposure on Alcohol Use During Adulthood: The Role of Neuropeptides. International Review of Neurobiology, 161, 53-93 (2021). https://doi.org/10.1016/bs.irn.2021.07.006

Hauser SR, Rodd ZA, Deehan GA, Liang T, Rahman S, Bell RL. Effects of Adolescent Substance Use Disorders on Central Cholinergic Function. International Review of Neurobiology 160, 175-221 (2021). doi: 10.1016/bs.irn.2021.07.008.

Rahman S*, Bell RL. Nicotinic Cholinergic Mechanisms in Alcohol Abuse and Dependence. Neuroscience of Alcohol-Mechanisms and Treatment 427-433 (2019).

Rahman S*, Alzarea, S. Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities. Progress in Molecular Biology and Transnational Science 167, 159-178 (2019). doi: 10.1016/bs.pmbts.2019.06.010.

Rahman S*, Bell RL. Nicotinic Cholinergic Mechanisms in Alcohol Abuse and Dependence. Neuroscience of Alcohol-Mechanisms and Treatment 427-431 (2019).

Bell RL, Sari Y, Rahman S. Alcohol and central glutamate activity: What goes up must come down. Neuroscience of Alcohol-Mechanisms and Treatment 453-461 (2019).

Abbas M, Alzarea S, Papke RL, Rahman S*. The α7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-alpha in the hippocampus in mice. Pharmacological Reports 71, 1168-1176 (2019).

Phelps BJ, Miller TM, Arens H, Hutchinson T, Lang KA, Muckey LM, Thompson N, Stanage S, Rahman S, Rawls SM. Cotinine Establishes a Conditioned Place Preference with Planarians. Neuroscience Letters 703, 145-148 (2019).

Alzarea S, Rahman S*. Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. Behavioral Brain Research 366,19-28 (2019).

Alotaibi G, Rahman S*. Effects of astroglial glutamate transporter activator in formalin-induced pain behavior in mice. European Journal of Pain 23, 765-783 (2019).

Alzarea S, Rahman S*. Effects of alpha-7 nicotinic allosteric modulator PNU 120596 on depressive-like behavior after lipopolysaccharide administration in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 86, 218-228 (2018).

Roni MA, Rahman S*. Lobeline attenuates ethanol withdrawal-induced depression-like behavior in mice. Alcohol 61, 63-70 (2017).

Abbas M, Alzarea S, Papke RL, Rahman S*. The α7 nicotinic acetylcholine receptor positive allosteric modulator Attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice. Drug Discoveries & Therapeutics 11, 206-211 (2017).

Islam N, Abbas M, Rahman S*. Neuropathic pain and lung delivery of nanoparticulate drugs: an emerging novel therapeutic strategy. CNS & Neurological Disorders-Drug Targets 16, 303-310 (2017).

Abbas M, Rahman S*. Effects of alpha-7 nicotinic acetylcholine receptor positive allosteric modulator on lipopolysaccharide-induced neuroinflammatory pain in mice. European Journal of Pharmacology 783, 85-91 (2016).

Bell RL, Hauser S, Rodd ZA, Liang T, Sari Y, McClintick J, Rahman S, Engleman EA. A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. International Review of Neurobiology 126, 179-260 (2016).

Rahman S*, Engleman EA, Bell RL. Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism. Progress Molecular Biology and Translational Science 137,183-201 (2016).

Bell RL, Hauser SR, McClintick J, Rahman S, Edenberg HJ, Szumlinski KK, McBride WJ. Ethanol-Associated Changes in Glutamate Reward Neurocircuitry: A Minireview of Clinical and Preclinical Genetic Findings. Progress in Molecular Biology and Translational Science 137, 41-85 (2016).

Sajja RK, Rahman S, Cucullo L. Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. Journal of Cerebral Blood Flow and Metabolism, 36, 539-554 (2016).

Roni MA, Rahman S*. Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacology Biochemistry and Behavior 139, 1-6 (2015).

Rahman S*, Engleman EA, Bell RL. Nicotinic receptor modulation to treat alcohol and drug dependence. Frontiers in Neuroscience-Neuropharmacology 8, (426), 1-11 (2015).

Roni MA, Rahman S*. The effects of lobeline on depression-like behavior and hippocampal dell proliferation following chronic unpredictable stress in mice. Neuroscience Letters 584, 7-11 (2015).

Roni MA, Rahman S*. The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice. Psychopharmacology 231, 2989-2998 (2014).

Sajja RK, Rahman S*. Nicotinic receptor partial agonists modulate alcohol deprivation effect in C57BL/6J in mice. Pharmacology Biochemistry and Behavior 110, 161-167 (2013).

Rahman S*. Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders. CNS & Neurological Disorders-Drug Targets 12, 633-640 (2013).

Sajja RK, Rahman S*. Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of Delta FosB in mice. Alcohol 47, 299-307 (2013).

Roni MA, Rahman S*. Antidepressant-like effects of lobeline in mice: behavioral, neurochemical and neuroendocrine evidence. Progress in Neuro-Psychopharmacology and Biological Psychiatry 41, 44-51 (2013).

Rahman S*, Prendergast MA. Brain cholinergic receptor system as a target for treating alcohol dependence. Recent Patents on CNS Drug Discovery 7, 145-150 (2012).

Sajja RK, Rahman S*. Nicotinic receptor ligands modulate chronic nicotine-induced ethanol consumption in C57BL/6J mice. Pharmacology Biochemistry and Behavior 102, 36-43 (2012).

Islam N, Rahman S*. Improved treatment of nicotine addiction and pulmonary drug delivery. Drug Discovery & Therapeutics, 6, 123-132 (2012).

Roni MA, Rahman S*. Neuronal nicotinic receptor ligand lobeline reduces anxiety-like behavior in mice. Neuroscience Letters 504, 237-241 (2011).

Sajja RK, Rahman S*. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35, 257-264 (2011).

Rahman S*. Brain nicotinic receptors as emerging targets for drug addiction: neurobiology to transnational science. Progress in Molecular Biology and Translational Science 98, 349-365 (2011).

Sajja RK, Dwivedi, C, Rahman S*. Nicotinic ligands modulate ethanol-induced dopamine function in mice. Pharmacology 86,168-73 (2010).

Meyer AC, Rahman S, Charnigo RJ, Dwoskin LP, Crabbe JC, Bardo MT. Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats. Genes, Brain and Behavior 9, 790-798 (2010).

Rahman S*. Targeting opioid receptors treatment for brain disorders. CNS & Neurological Disorders-Drug Targets 9, 128 (2010).

Hasan SMR, Hossain, MM, Akter R, Jamila, M, Mazumder MEH, Alam MA, Faruque, A, Rana S, Rahman S*. Analgesic activity of the different fractions of the aerial parts of Commelina benghalensis Linn. International Journal of Pharmacology 6, 63-67 (2010).

Bell RL, Eilier BA, Cook, JB, Rahman S*. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 43, 581-592 (2009).

Hasan R. S.M., Jamila, M, Majumder MM, Akter R., Hossain MM., Mazumder MEH, Alam, MA, Jahangir R, Rana, MS, Arif M. and Rahman S*. Analgesic and antioxidant activity of the Hydromethanolic extract of Mikania scandens (L.) Willd. Leaves. American Journal of Pharmacology Toxicology 4, 1-7 (2009).

Hasan, SMR, Hossain, MM, Akter R, Jamila, M, Mazumder MEH, Faruque A, Rahman S*. Sedative and anxiolytic effects of different fractions of Commelina benghalensis. Drug Discoveries & Therapeutics 3, 221-227 (2009).

Hasan SMR, Hossain, MM, Akter R, Jamila, M, Mazumder MEH, Rahman, S*. DPPH free radical scavenging activity of some Bangladeshi medicinal plants. Journal of Medicinal Plants Research, 3, 875-879 (2009).

Rahman S*. Drug Addiction and Brain Targets: from Preclinical research to Pharmacotherapy. CNS & Neurological Disorders-Drug Targets 7, 391-392 (2008).

Rahman S*, Lopez-Hernandez G, Corrigall WA., Papke RL, Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS and Neurological Disorders-Drug Targets 7, 422-441 (2008).

Rahman S, Neugebauer NM., Zhang Z, Crooks PA, Dwoskin LP, Bardo MT, The novel nicotinic receptor antagonist N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. European Journal of Pharmacology 601, 103-105 (2008).

Rahman S, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. Region-specific effects of N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on nicotine-induced increase in extracellular dopamine in vivo. British Journal of Pharmacology 153, 792–804 (2008).

Rahman S, Bardo MT. Environmental enrichment increases amphetamine-induced glutamate neurotransmission in the nucleus accumbens: a neurochemical study. Brain Research 1197, 40-46 (2008).

Islam N, Rahman S*, Pulmonary drug delivery: Implication for new strategy for pharmacotherapy of neurodegenerative disorders. Drug Discoveries & Therapeutics 5, 264-276 (2008).

Mazumder MEH, Rahman S*. Pharmacological evaluation of Bangladeshi Medicinal Plants for antioxidant activity. Pharmaceutical Biology 46, 704-709 (2008)

Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of novel N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide on acute and repeated nicotine-induced increases in extracellular dopamine response in rat nucleus accumbens. Neuropharmacology 52, 755-763 (2007).

Rahman S*, Zhang J., Engleman E, Corrigall WA. Neuroadaptive changes in mesolimbic dopamine system after chronic nicotine self-administration: A microdialysis study. Neuroscience 129, 415-424 (2004).

Rahman S*, Zhang J, Corrigall WA. Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine pre-exposure. Neurochemical Research 29, 1687-1693 (2004).

Rahman S*, Zhang J, Corrigall WA. Effect of nicotine exposure on sulpiride-induced dopamine release in the nucleus accumbens. European Journal Pharmacology 494, 31-34 (2004).

Rahman S*, Zhang J, Corrigall, WA. Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area in vivo microdialysis study. Neuroscience Letters 348, 61-64 (2003).

Rahman S, McBride WJ. Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the VTA. Journal of Neurochemistry 80, 646-654 (2002).

Rahman S and McBride WJ. Dopamine D1-D2 receptor interaction within the nucleus accumbens mediates long-loop negative feedback to the VTA. Journal of Neurochemistry 77, 1248-1255 (2001).

Rahman S, Engleman E, Simon J, and McBride WJ. Negative interaction of D2 receptor antagonist and GBR-12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. European Journal Pharmacology 414, 37-44 (2001).

Rahman S*, Hasnat A, Hasan CM, Rashid MA and Ilias M. Pharmacological Evaluation of traditionally used medicinal plants of Bangladesh. Pharmaceutical Biology 39, 1-6 (2001).

Rahman S, McBride WJ. Feedback control of mesolimbic somatodendritic dopamine release in rat brain. Journal of Neurochemistry 74, 684-692 (2000).

Rahman S, Li, PP, Kish SJ, Young LT, Kofman O, Warsh JJ. Reduced [3H]cAMP binding in bipolar affective disorder. Journal of Neurochemistry 68, 297-304 (1997).

Kofman O, Rahman S, Li PP, Warsh JJ. Lithium and carbamazepine differentially affect locomotion and cAMP binding stimulated by cholera toxin. Biological Psychiatry, 39, 594-595 (1996)

Rahman S, Li PP, Kish SJ, Young LT, Warsh JJ. Decreased [3H] cAMP binding in postmortem brain in bipolar disorder. Biological Psychiatry, 39, 583-584 (1996)

Rahman S and Neuman RS. Calcimycin, cyclopiazonic acid and Thapsigargin mimic 5-hydroxytryptamine in facilitating N-methyl-D-aspartate depolarization of cortical neurons. British Journal of Pharmacology 119, 877-884 (1996)

Rahman S, Neuman RS. Characterization of metabotropic glutamate receptor mediated facilitation of N-methyl-D-aspartate depolarization of neocortical neurons. British Journal of Pharmacology 117, 675-683 (1996).

Rahman S, McLean J, Darby-King A, Paterno G, Reynolds J, Neuman RS. Loss of cortical serotonin 5-HT2A signal transduction in senescent rats: reversal following inhibition of protein kinase C. Neuroscience 66, 891-901 (1995).

Neuman RS, Rahman S. Calcium mobilizing compounds mimic 5-HT Induced facilitation of N-methyl-D-aspartate depolarization. Behavioral Brain Research 73, 273-275 (1995).

Rahman S, Neuman RS. Multiple mechanisms of serotonin (5-HT2A) Receptor desensitization. European Journal of Pharmacology 238, 173-180 (1993).

Rahman S, Neuman RS. Myo-inositol reduces serotonin (5-HT2A) Receptor induced homologous and heterologous desensitization. Brain Research 631, 349-351 (1993).

Rahman S, Neuman RS. Activation of 5-HT2A receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate. European Journal of Pharmacology 231, 347-354 (1993).

CONFERENCE/MEETING ABSTRACTS:
Over 175 Abstracts or Presentations from regional/national and international meetings/conferences or symposiums.

INVITED PRESENTATIONS/SEMINARS:
Over 50 invited presentations/seminars at numerous Academic Institutions and Professional Meetings in the USA, Canada and overseas.